Matt joined Kilburn & Strode in October 2019 and is currently training to become a European and UK patent attorney in the Life Sciences and Chemistry group.

His work at Kilburn & Strode spans technologies including cell therapies, regenerative medicine, molecular biology, vaccines, antibodies, diagnostics, AI-driven drug discovery and synthetic biology. Matt has experience in handling European patent prosecution, portfolio management and EPO oppositions.
Matt gained a BSc (Hons) in Biochemistry from UCL in 2017, with a particular interest in genetics and epigenetics. Following this he obtained an MSc in Cellular Therapy from Bench to Market at King’s College London, a course specialising in how to navigate the challenging regulatory and business environments of these emerging therapies. Graduating in 2018 with a distinction, Matt’s thesis was a business plan to commercialise a stem cell-derived therapy for Parkinson’s disease.
Before joining Kilburn & Strode, Matt worked at the Cell & Gene Therapy Catapult, a centre of excellence which supports the UK advanced therapies sector by bridging the gap between academia and industry. As part of the process development team, he became proficient in the production and downstream processing of viral vector material, 2D and 3D cell culture, non-viral gene editing tools, immunotherapy production platforms and ddPCR.


PGCert (Merit) IP Law, Queen Mary University of London
MSc (Dist) Cellular Therapy from Bench to Market, King’s College London
BSc (Hons) Biochemistry, UCL


Chartered Institute of Patent Attorneys (CIPA) – Student member
The Institute of Professional Representatives before the European Patent Office (EPI) - Student member

M. Aldridge & M. Newton, ‘AI in Drug Repurposing’, Kilburn & Strode, (2020)
M. Aldridge, M.  Newton & H. Harden, ‘AI Diagnostics & Digital Healthcare’, Kilburn & Strode, (2020)

Cookies improve the way our website works. By using this website you are agreeing to our use of cookies. For more information see our cookie policy I accept